Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics, Inc. was founded in 2011 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone203-304-2499
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees15
Next Earnings Date2/27/2020 (Estimated)
OptionableNot Optionable
Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions
What is Trevi Therapeutics' stock symbol?
Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."
How were Trevi Therapeutics' earnings last quarter?
Trevi Therapeutics Inc (NASDAQ:TRVI) posted its quarterly earnings data on Thursday, November, 14th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.07. View Trevi Therapeutics' Earnings History.
When is Trevi Therapeutics' next earnings date?
What price target have analysts set for TRVI?
5 brokers have issued 12-month price objectives for Trevi Therapeutics' stock. Their forecasts range from $14.00 to $20.00. On average, they anticipate Trevi Therapeutics' share price to reach $16.75 in the next twelve months. This suggests a possible upside of 204.5% from the stock's current price. View Analyst Price Targets for Trevi Therapeutics.
What is the consensus analysts' recommendation for Trevi Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevi Therapeutics.
Has Trevi Therapeutics been receiving favorable news coverage?
News headlines about TRVI stock have trended very negative recently, InfoTrie reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Trevi Therapeutics earned a media sentiment score of -3.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Trevi Therapeutics.
Are investors shorting Trevi Therapeutics?
Trevi Therapeutics saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 26,100 shares, a decline of 30.4% from the January 15th total of 37,500 shares. Based on an average daily trading volume, of 13,600 shares, the days-to-cover ratio is presently 1.9 days. Approximately 1.0% of the shares of the stock are sold short. View Trevi Therapeutics' Current Options Chain.
Who are some of Trevi Therapeutics' key competitors?
Some companies that are related to Trevi Therapeutics include Avid Bioservices (CDMO), Avedro (AVDR), DURECT (DRRX), Urovant Sciences (UROV), Galera Therapeutics (GRTX), Mirum Pharmaceuticals (MIRM), Rigel Pharmaceuticals (RIGL), Recro Pharma (REPH), Verrica Pharmaceuticals (VRCA), Lannett (LCI), Kindred Biosciences (KIN), Corbus Pharmaceuticals (CRBP), Stemline Therapeutics (STML), INDIVIOR PLC/S (INVVY) and Evolus (EOLS).
What other stocks do shareholders of Trevi Therapeutics own?
Who are Trevi Therapeutics' key executives?
Trevi Therapeutics' management team includes the folowing people:
- Ms. Jennifer L. Good, Co-Founder, CEO, Pres & Director (Age 54)
- Mr. Thomas R. Sciascia, Co-Founder and Chief Medical Officer (Age 66)
- Mr. Christopher J. Seiter, Chief Financial Officer (Age 52)
- Dr. Helena Brett-Smith M.D., Chief Devel. Officer (Age 62)
- Dr. Amale Hawi, Sr. VP of CMC (Age 65)
When did Trevi Therapeutics IPO?
(TRVI) raised $70 million in an IPO on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.
Who are Trevi Therapeutics' major shareholders?
Trevi Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (3.29%). Company insiders that own Trevi Therapeutics stock include Anne Vanlent, Invest A/S Lundbeckfond and Jennifer L Good. View Institutional Ownership Trends for Trevi Therapeutics.
Which major investors are selling Trevi Therapeutics stock?
How do I buy shares of Trevi Therapeutics?
Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Trevi Therapeutics' stock price today?
One share of TRVI stock can currently be purchased for approximately $5.50.
How big of a company is Trevi Therapeutics?
What is Trevi Therapeutics' official website?
How can I contact Trevi Therapeutics?
Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at 203-304-2499 or via email at [email protected]
MarketBeat Community Rating for Trevi Therapeutics (NASDAQ TRVI)
MarketBeat's community ratings are surveys of what our community members think about Trevi Therapeutics and other stocks. Vote "Outperform" if you believe TRVI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVI will underperform the S&P 500 over the long term. You may vote once every thirty days.
